Mino-León D, Hernández-Carvajal I, Peredo-Silva L, Búrbano-Martínez G

Language: Spanish
References: 15
Page: 15-19
PDF size: 201.88 Kb.

ABSTRACT

Introduction: The relevance of medications for health depends on their quality, accessibility and appropriate use. Objective: To determine the potential therapeutic value of antibiotics that are not included in the World Health Organization Essential Medicines List (EML) but that are part of the National Essential Medicines List (NEML) of the Mexican Ministry of Health, and categorize them according to their intrinsic value. Method: Descriptive analysis of antibiotics not included in the 2013 World Health Organization EML; literature review to obtain efficacy and safety evidence; and application of quality and intrinsic value scales. Results: Four hundred and fifty-two abstracts were identified for 19 antibiotics; 56.9 % were excluded; 195 clinical trials were reviewed in full-text articles, out of which 37.9 % were of good quality, and intrinsic value was determined; 54 % were superiority studies, whereas 46 % were non-inferiority or equivalence studies; 32 % of the antibiotics were classified without intrinsic value and nearly 50 % were inconclusive. Conclusion: An elevated proportion of antibiotics of the NEML had uncertain or no intrinsic value, which favors their inappropriate use, bacterial resistance and puts the population at risk.

REFERENCES

1. World Health Organization. The world medicines situation 2004. Ginebra, Suiza: World Health Organization; 2004.

2. World Health Organization. The rational use of drugs. Report of the conference of experts, Nairobi, 25-29 November 1985. Ginebra, Suiza: World Health Organization; 1987.

3. Hoyle M. Historical lifetimes of drugs in England: application to value of information and cost-effectiveness analyses. Value Health. 2010;13: 885-892.

4. Diogene E, Figueras A. What public policies have been more effective in promoting rational prescription of drugs? J Epidemiol Community Health. 2011;65:87-88.

5. Rico-Alba I, Figueras A. The fuzzy line between needs, coverage, and excess in the Mexican formulary list: an example of qualitative market width analysis. Eur J Clin Pharmacol. 2013;69:949-956.

6. Dreser A, Wirtz VJ, Corbett KK, Echániz G. Uso de antibióticos en México: revisión de problemas y políticas. Salud Publica Mex. 2008; 50:S480-S487.

7. Floyd JS, Psaty BM. The potential risks of expedited approval of drugs for acute bacterial infections. JAMA Intern Med. 2014;174:1436-1437.

8. López-Navas A, García-Escribano Ráez N, Flores-Juberías Á, Suárez- Gea ML. Procedure for the marketing authorization of an antibacterial agent. Enferm Infecc Microbiol Clin. 2014;32:529-532.

9. Rico-Alba I, Figueras A. The evolution of reference drug lists and clinical practice guidelines in the public health system of a middle-income country. Br J Clin Pharmacol. 2014;78:410-421.

10. Laporte JR, Porta M, Capella D. Drug utilization studies: a tool for determining the effectiveness of drug use. Br J Clin Pharmacol. 1983;16: 301-304.

11. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1-12.

12. World Health Organization. Selection of essential medicines. Ginebra, Suiza: World Health Organization; 2016.

13. Perumal-Pillay VA, Suleman F. Selection of essential medicines for South Africa: an analysis of in-depth interviews with national essential medicines list committee members. BMC Health Serv Res. 2017;17:17.

14. Management Sciences for Health. MSD-3: Managing access to medicines and health technologies. EE. UU.: Management Sciences for Health; 2012.

15. Ozolins M, Eady EA, Avery AJ, Cunliffe WJ, Po AL, O’Neill C, et al. Comparison of five antimicrobial regimens for treatment of mild to moderate inflammatory facial acne vulgaris in the community: randomised controlled trial. Lancet. 2004;364 2188-2195.